Oncotarget

Research Papers:

Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma

Zuzana Macek Jilkova, Ayca Zeybek Kuyucu, Keerthi Kurma, Séyédéh Tayébéh, Ahmad Pour, Gaël S. Roth, Giovanni Abbadessa, Yi Yu, Brian Schwartz, Nathalie Sturm, Patrice N. Marche, Pierre Hainaut, Thomas Decaens _

PDF |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2018; 9:11145-11158. https://doi.org/10.18632/oncotarget.24298

Metrics: PDF 279 views  |   HTML 268 views  |   ?  


Abstract

Zuzana Macek Jilkova1,2, Ayca Zeybek Kuyucu1,2,3, Keerthi Kurma1,2, Séyédéh Tayébéh Ahmad Pour1,2, Gaël S. Roth1,2,6, Giovanni Abbadessa4, Yi Yu4, Brian Schwartz4, Nathalie Sturm1,2,5, Patrice N. Marche1,2, Pierre Hainaut1,2 and Thomas Decaens1,2,6

1Université Grenoble-Alpes, Saint-Martin-d’Hères, France

2Institute for Advanced Biosciences, Research Center Inserm U1209/CNRS 5309/UGA, Grenoble, France

3Izmir Institute of Technology, Department of Bioengineering, Izmir, Turkey

4ArQule Inc., Woburn, MA, USA

5CHU-Grenoble Département d’Anatomie et de Cytologie Pathologiques, La Tronche, France

6CHU-Grenoble Clinique Universitaire d’Hépato-Gastroentérologie, Pôle Digidune, France

Correspondence to:

Thomas Decaens, email: tdecaens@chu-grenoble.fr

Zuzana Macek Jilkova, email: zuzana.mjilkova@gmail.com

Keywords: liver cancer; combination treatment; fibrosis; DEN-induced model; AKT inhibitor

Received: August 11, 2017     Accepted: January 13, 2018     Published: January 23, 2018

ABSTRACT

The prognosis of patients with advanced hepatocellular carcinoma (HCC) is very poor. The AKT pathway is activated in almost half of HCC cases and in addition, long term exposure to conventional drug treatment of HCC, sorafenib, often results in over-activation of AKT, leading to HCC resistance. Therefore, it is important to assess the safety and the efficacy of selective allosteric AKT inhibitor ARQ 092 (Miransertib) in combination with sorafenib.

Here, we demonstrated in vitro that the combination of ARQ 092 with sorafenib synergistically suppressed proliferation, promoted apoptosis, and reduced migration. To test the effect of the combination in vivo, rats with diethylnitrosamine-induced cirrhosis and fully developed HCC were randomized and treated with vehicle, sorafenib, ARQ 092 or the combination of ARQ 092 with sorafenib; (n=7/group) for 6 weeks. Tumor progression, size of tumors and the mean tumor number were significantly reduced by the combination treatment compared to the control or single treatments. This effect was associated with a significant increase in apoptotic response and reduction in proliferation and angiogenesis. Sirius red staining showed a decrease in liver fibrosis. Moreover, treatments improved immune response in blood and in tumor microenvironment.

Thus, the combination of ARQ 092 with sorafenib potentiates inhibition of tumor progression and gives the possibility of therapeutic improvement for patients with advanced HCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24298